ChadKOhMD

Chief Medical Officer of AEON BioPharma

Dr. Oh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1990 - 1995
Rush University Medical CenterResidency, Pediatrics, 1987 - 1990
McGaw Medical Center of Northwestern UniversityFellowship, Neurology, 1984 - 1987
Kyung Hee University College of MedicineClass of 1983, MD

PubMed

56 citations
Smoking and idiopathic pulmonary fibrosis.
Chad K. Oh, Lynne Murray, Nestor A. Molfino
Pulmonary Medicine. 2012-02-19
32 citations
Biology of the Interleukin-9 Pathway and its Therapeutic Potential for the Treatment of Asthma
Chad K. Oh, Donald Raible, Gregory P. Geba, Nestor A. Molfino
Inflammation & Allergy Drug Targets. 2011-05-31
100 citations
Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies...
Joseph M. Parker, Chad K. Oh, Craig LaForce, S. David Miller, David S. Pearlman
BMC Pulmonary Medicine. 2011-02-28

Image-Guided Superficial Radiotherapy Is 99.3 Percent Effective in Treating Common Skin Cancers Without Surgery, Study SuggestsSeptember 10th, 2021
AEON Biopharma Appoints Dr. Chad K. Oh as Chief Medical Officer to Lead Clinical Development of ABP-450 Across Several Therapeutic IndicationsJune 9th, 2021